Kalaris Therapeutics (KLRS) stock: insider trades, news & valuation
Net buyingShare price and insider trades
Kalaris Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $6.2M and 1 sold $13K of KLRS stock on the open market.
Get emailed when insiders cluster-buy stocks like KLRS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
KLRS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | $1.2M | 1 | — | 0 |
| Q1 2026 | — | 0 | $13K | 1 |
| Q4 2025 | $5.0M | 1 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 Kalaris Therapeutics, Inc. insiders reported open-market purchases totaling $6.2M, while 1 insider reported sales totaling $13K. 0 of 1 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| May 22SEC | Biocapital, L.p. Samsara10% Owner | Buy | 244,3002,224,147 held (+12%) | $4.83 | $1.2M | -51.1% | — |
| Mar 23SEC | Brett R HagenChief Accounting Officer | Sell | 1,915 | $6.72 | $13K | -64.9% | — |
| Feb 17SEC | Samsara Opportunity Fund, L.P.10% Owner | Buy | 479,8471,979,847 held (+32%) | $10.42 | $5.0M | -77.4% | — |
Insiders at Kalaris Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Samsara Opportunity Fund, L.P.10% Owner | $5.0M | — | Feb 17, 2026 | — |
| Biocapital, L.p. Samsara10% Owner | $1.2M | — | May 22, 2026 | — |
| Brett R HagenChief Accounting Officer | — | $13K | Mar 23, 2026 | — |
KLRS stock: common questions
Are Kalaris Therapeutics, Inc. insiders buying KLRS stock?
In the past 12 months, 2 insiders reported open-market purchases of KLRS worth $6.2M. The latest was 10% Owner Biocapital, L.p. Samsara bought $1.2M of KLRS at $4.83 — first open-market purchase in our records.
Are Kalaris Therapeutics, Inc. insiders selling KLRS stock?
1 insiders reported sales worth $13K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is KLRS's 52-week range?
Over the past year KLRS has traded between $2.36 and $10.98. It last closed at $2.36 on Oct 9, 2026.